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Cost-Effectiveness of Intensive Exercise Therapy
Directly Following Hospital Discharge in Patients
With Arthritis: Results of a Randomized
Controlled Clinical Trial
YVETTE BULTHUIS,1 SABRINA MOHAMMAD,2 LOUISE M. A. BRAAKMAN-JANSEN,1
K. WIEPKE DROSSAERS-BAKKER,3 AND MARTIN A. F. J. VAN DE LAAR3
Objective. To estimate the cost-utility and cost-effectiveness of a 3-week intensive exercise training (IET) program
directly following hospital discharge in patients with rheumatic diseases.
Methods. Patients with arthritis who were admitted to the hospital because of a disease activity flare or for elective hip
or knee arthroplasty were randomly assigned to either the IET group or usual care (UC) group. Followup lasted 1 year.
Quality-adjusted life years (QALYs) were derived from Short Form 6D scores and a visual analog scale (VAS) rating
personal health. Function-related outcome was measured using the Health Assessment Questionnaire, the McMaster
Toronto Arthritis (MACTAR) Patient Preference Disability Questionnaire, and the Escola Paulista de Medicina Range of
Motion scale (EPMROM). Costs were reported from a societal perspective. Differences in costs and incremental cost-
effectiveness ratios (ICERs) were estimated.
Results. Data from 85 patients (50 IET and 35 UC) could be used for health-economic analysis. VAS personal health–
based QALYs were in favor of IET. Function-related outcome showed statistically significant improvements in favor of
IET over the first 6 months, according to the MACTAR (P < 0.05) and the EPMROM (P < 0.01). At 1-year followup, IET
was €718 less per patient. The ICER showed a reduction in mean total costs per QALY. In 70% of cases the intervention
was cost-saving.
Conclusion. IET results in better quality of life at lower costs after 1 year. Thus, IET is the dominant strategy compared
with UC. This highlights the need for implementation of IET after hospital discharge in patients with arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) and osteoarthritis (OA) have a
different pathophysiologic basis. However, patients who
have either form of arthritis experience pain and a gradual
decline in muscle strength, eventually resulting in loss of
function and quality of life. Hospitalization is indicated in
patients with arthritis who experience a disease activity
flare or who require elective joint replacement. During
hospitalization, an increased decline of function is ob-
served (1). Recently, in the Disabled Arthritis Patients
Post-hospitalisation Intensive Exercise Rehabilitation
(DAPPER) study (2), we have shown the beneficial effects
of intensive exercise training (IET) directly following hos-
pital discharge of arthritis patients with disease flare or
after elective joint replacement. This finding is in line with
earlier studies in patients with arthritis that evaluated IET
on an inpatient basis and on an ambulatory basis (3–5).
Usual care for patients with arthritis following hospital-
ization due to a flare of disease activity or for joint replace-
ment is not standardized and depends upon local custom,
health care system, and preferences of the patient, among
other things. Nowadays, health care policy is based on
evidence of effectiveness and, conversely, on health eco-
nomic considerations. Thus the implementation of novel
treatment strategies should be based on evidence of effec-
tiveness as well as on an acceptable balance between costs
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and effectiveness. Up to now, only a limited number of
studies have reported the cost-effectiveness of exercise in
patients with arthritis (6–10). However, patients with ac-
tive disease were excluded.
This report addresses the health economic aspects of an
IET program compared with usual care (UC) for patients
with arthritis following hospitalization due to a flare in
disease activity or for elective knee or hip replacement.
The cost-effectiveness analysis was performed alongside
the randomized controlled clinical trial.
PATIENTS AND METHODS
Patients. Patients were recruited from 4 Dutch hospitals
(Medisch Spectrum Twente, Enschede; Twenteborg ziek-
enhuis, Almelo; Sint Maartenskliniek, Nijmegen; and Isala
klinieken, Zwolle). Patients were eligible when they were
admitted either due to a flare in disease activity or for
elective knee or hip replacement. Additional inclusion
criteria were age 18 years and either RA according to the
American College of Rheumatology (formerly the Ameri-
can Rheumatism Association) 1987 criteria (11) or polyar-
ticular OA. Exclusion criteria were presence of serious
cardiac disease (New York Heart Association criteria class
III and IV) (12), incapacitating pulmonary disease (Gold
stage IV) (13), serious hypertension (diastolic blood pres-
sure 110 mm Hg), pregnancy, insufficient understanding
of the Dutch language, and functional incapacity (Stein-
brocker functional class 4) (14). A signed consent form was
obtained from all participants.
Design. The DAPPER study is a randomized controlled
clinical trial. In summary, consecutive eligible patients
who gave informed consent were included and random-
ized blockwise to either the intervention group (IET) or the
control group (UC). Directly following discharge, patients
in the IET group were referred to a dedicated convalescent
resort to receive 3 weeks of intensive exercise training.
Thereafter, the IET group received regular care only.
In contrast, after discharge the patients in the UC group
received usual care at the discretion of their attending
physician only. Standard usual care after an elective joint
replacement often consists of physical therapy once or
twice weekly at a home-based setting. In case of comor-
bidity or polyarticular OA complication, rehabilitation re-
ferral to a nursing home is customary. Usual care after a
disease flare is diverse, ranging from no additional therapy
to physical therapy and ergotherapy at home. Outcome
assessments were performed at baseline and after 3, 13, 26,
and 52 weeks. Costs were measured prospectively by
monthly questionnaires.
Intervention. Directly following discharge, the IET
group received a 3-week intensive exercise program at the
European Care Residence and Resort “Groot Stokkert,”
which offers hotel facilities and professional care for dis-
abled persons. During their 3-week stay, patients from the
IET group were trained twice a day by physical therapists
for 75 minutes per session. The goals of the training were
improvement of range of motion, muscle strength, aerobic
capacity, physical function, and daily activities. The ther-
apy sessions were administered individually and in
groups. In the first 2 weeks, treatment focused on individ-
ual limitations (range of motion, strength, balance, aerobic
capacity, and simple functionality). Aerobic capacity
training occurred daily on a submaximal level. Hydrother-
apy was applied after sufficient wound healing. During the
third week, the training focused on the functional capaci-
ties as prioritized by the patient. A group education pro-
gram was administered twice per week. This program was
based on the self-management training for patients with
arthritis developed by Lorig et al (15) and modified for The
Netherlands by Taal et al (16).
Health outcome. Utilities. Utilities refer to the prefer-
ences individuals or society may have for any particular
health state (17) and a valuation of the health of the patient
ranging from 0 (equivalent to death) to 1 (full health).
Utilities are used to calculate quality-adjusted life years
(QALYs). A QALY is a composite index that includes
effects in terms of both quality of life (utility) and the
duration of time in such a health state (17). QALYs are an
accepted measure for resource allocation decisions involv-
ing diverse treatments and patient populations (18).
For the present study, utilities were assessed using the
Short Form 6D (SF-6D) and a 100-mm visual analog scale
(VAS). The SF-6D utility index was calculated from the
RAND 36-item health survey 1.0 (RAND-36) questionnaire
(19). The RAND-36 includes the same items as those in the
Short Form 36 (SF-36) and measures general health status.
The RAND-36 comprises 36 items on physical and social
functioning, role limitations, mental health, vitality, pain,
and general health perception (20). The VAS score ranges
from 0 (worst imaginable health) to 100 (best imaginable
health).
Functional ability. Outcome expressed as functional
ability was calculated according to the Health Assessment
Questionnaire (HAQ) (21,22), the McMaster Toronto Ar-
thritis (MACTAR) Patient Preference Disability Question-
naire (23,24), and the Escola Paulista de Medicina Range of
Motion scale (EPMROM) (25). The HAQ score ranges from
0 (no disability) to 3 (severe disability); the MACTAR
followup score ranges from 21 to 77 points (lower scores
reflect better functional ability). The followup assessments
focus on change in ability to perform impaired activities
and evaluate the patient’s health status by asking ques-
tions on general health; quality of life; and physical, social,
and emotional well-being. The EPMROM evaluates 10 dis-
tinct movements of joints on both sides of the body, and
the score varies from 0 (no limitation) to 30 (severe limi-
tation).
Costs. Costs were assessed using the societal perspec-
tive and were valued in accordance with the Dutch guide-
lines for pharmacoeconomic research (26) including direct
and indirect medical costs and indirect nonmedical costs.
All unit cost prices were based on the year 2003 and were
expressed in euros (€).
To estimate the costs of the convalescence program
(IET), College Tarieven Gezondheidszorg/Zorgautoriteit
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in oprichting (CTG/ZAio) charges were used (www.ctg-
zaio.nl). The cost per day of the IET program was com-
posed as follows: 1) accommodation €90, 2) nursing care
€10.50, 3) individual physical therapy €21.50, and 4)
group therapy €37.25. During the weekend no therapy was
administered. The cost per weekday per IET patient was
valued at €159.25. The cost per weekend day per IET
patient was €100.50. The total cost of the intervention was
estimated at €2,991 per patient.
Medical costs were based on the 2003 Dutch governmen-
tal charges (CTG/ZAio) or, whenever applicable, on the
market prices. The general practitioner was valued at
€20.20 per visit. Medical specialist visits were valued at an
average charge of €57.65. The physical therapist was val-
ued at €21.50 per visit. All other paramedical and alterna-
tive therapists (such as occupational therapists and social
workers) were separately valued according to average
prices of the professions in The Netherlands. The average
price was €32.60 per visit. Medication was valued accord-
ing to the Dutch Pharmacotherapeutic Compass (27) in-
cluding the 6% price per prescription to cover pharmacist
fees.
For hospital admissions, the number of days spent in the
hospital and the type of hospital were recorded. Hospital-
ization days were valued according to the prices declared
by the financial administration of the hospitals. The aids
used for physical restrictions were recorded as were the
actual costs incurred by the patients.
Nonmedical costs were based on Dutch standard prices
reflecting societal costs for economic evaluations (28).
These costs included travel costs required to obtain health
care, the costs of absenteeism from work, professional
domestic care, paid domestic help, and informal care (the
number of hours per week patients received help from
family or friends). Absenteeism was valued using the hu-
man-capital method in which productivity costs are cal-
culated for the entire absent period. Absenteeism from
paid work was recorded on a per-day basis. Monthly in-
come and regular working hours were recalculated to
value a day’s income (28,29).
Professional domestic care was valued at €30.70 per
hour. The costs of paid domestic help and informal care
were valued as reported by the patients with a maximum
of 28 hours per week in order to prevent overreporting.
When actual costs were unavailable, an average cost per
hour of €8.00 was imputed.
Statistical analysis. Results were analyzed for patients
who completed at least 6 of the 12 monthly questionnaires
on costs. Results are expressed as QALYs and measures of
physical function. The time-integrated summary score (the
area under the curve [AUC]) of the utilities was calculated
to define the quality of life per period (0–6 months and
0–1 year).
The scores of the HAQ, MACTAR, and EPMROM were
presented as change scores from baseline. Between-group
differences in outcome measurements were analyzed per
period by Student’s t-test for unpaired observations.
The costs are presented as the arithmetic mean SD per
patient per group. The between-group differences in re-
source use were analyzed per period by Mann-Whitney U
test. Mean incremental costs per patient and study period
were calculated and 95% confidence intervals (95% CIs)
were calculated using double-sided bootstrapping.
The incremental cost-utility ratio (ICER) was calculated
by dividing the incremental costs for the IET group by the
gained QALYs derived from IET. The ICER is expressed as
costs per QALY gained. The incremental cost-effectiveness
ratio (ICER) for function measures was calculated by di-
viding the extra costs for the IET group by the gained units
of effectiveness. These ICERs are expressed as costs per
score points. The 95% CIs of the ratios were estimated
with bootstrapping. ICERs were only calculated when
group differences were significantly different. Costs and
health outcome were not discounted because the time
horizon of this study was less than 1 year and no modeling
beyond the observed period was performed.
RESULTS
Study participants. The DAPPER trial included 114 pa-
tients with arthritis who were admitted to the hospital
because of a flare in disease activity or for elective joint
replacement of the hip or knee. Cost questionnaires were
completed by 85 of the patients (75%; 50 IET and 35 UC).
Twenty-nine of the patients (10 IET and 19 UC) did not
complete the questionnaires, but they did not differ from
the other patients in the DAPPER trial with respect to sex,
age, work, or education.
The demographic and baseline disease characteristics of
the patients in this health economic analysis are presented
in Table 1. Differences between groups were not statisti-
cally significant.
Health outcome results. SF-6D–based QALYs were
similar in both groups. VAS-based QALYs were in favor of
IET (P  0.05) for both periods (Table 2).
Function-related outcome was similar according to the
HAQ. However, the MACTAR (P  0.05) and the EPM-
ROM (P  0.01) showed statistically significant improve-
ments in favor of IET during the first 6 months (Table 2).
Cost results. The amount of medical and nonmedical
resource use during the followup is presented in Table 3.
For both periods, a difference in favor of the IET group was
observed in the number of visits for paramedical treat-
ments (P  0.01). Patients from the UC group visited
physical therapists 1.8 times more frequently compared
with the IET group. For the other variables, including
hospitalization, no significant differences in the amount of
resource use were found.
Mean costs per patient per year by cost category and
treatment group are listed in Table 4. Mean total costs from
a societal perspective were €718 lower per patient per year
(95% CI€7,553, €3,660) for the IET group compared with
the UC group. When excluding the price of the IET pro-
gram, mean incremental costs per patient were €3,709
lower for IET. After 6 months of followup, the mean in-
cremental costs per patient was €804 higher for IET (95%
CI €2,595, €3,996). When excluding the price of the IET
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program, the mean incremental costs per patient was
€2,068 lower for IET (data not shown).
The observed difference in costs between groups was
mainly generated by the cost of hospitalization. Therefore,
further specification of these costs was explored. The main
difference in hospitalization costs could be explained by a
small group of patients from the UC group. Immediately
after initial discharge from the hospital, these patients
(mainly diagnosed with OA) were referred to a nursing
home for an average of 47 days. This resulted in €31,000
extra costs for the UC group. In addition, during followup
patients from the UC group who were hospitalized because
of a second elective hip or knee arthroplasty stayed in the
hospital longer on average compared with patients from
the IET group, which explains a difference in total costs of
€21,000 between groups (results not shown).
Cost-utility. The incremental cost-utility ratio (based on
the AUC of the VAS personal health) after 6 months of
followup was €20,100 (€804/0.04) per QALY gained (95%
Table 1. Comparison of demographic and baseline disease characteristics of the 85
patients who completed the cost questionnaires in the intensive exercise therapy (IET)






Female sex 42 (84) 28 (80)
Age, median (range) years 69 (44–89) 69 (36–88)
Indication of hospitalization
Disease flare† 5 (10) 4 (12)
Elective knee or hip replacement 45 (90) 31 (88)
Diagnosis (of patients with elective knee or hip replacement)
Rheumatoid arthritis 9 (20) 11 (35)
Osteoarthritis 36 (80) 20 (65)
Years since continuous symptoms onset, median (range) 8 (2–46) 11 (1–50)
Marital status
Single 24 (48) 12 (34)
Employment status
Paid work 3 (6) 1 (3)
Health-related unemployment 5 (10) 6 (17)
Retired, housewife, volunteer, other 42 (84) 28 (80)
* Values are the number (percentage) unless otherwise indicated. Differences between groups were not
statistically significant (Mann-Whitney U test or chi-square test where appropriate).
† Patients with disease flare were all diagnosed with rheumatoid arthritis.
Table 2. Health outcome measures per time period comparing patients in the intensive




(n  35) Difference
QALYs (based on the SF-6D)†
0–6 months 0.31  0.02 0.31  0.02 –
0–1 year 0.62  0.04 0.61  0.03 0.01
QALYs (based on the VAS)†
0–6 months 0.38  0.10 0.34  0.10 0.04‡
0–1 year 0.77  0.17 0.68  0.20 0.09‡
HAQ§
0–6 months 0.64  0.55 0.63  0.54 0.01
0–1 year 0.73  0.55 0.67  0.59 0.06
MACTAR§
0–6 months 11.8  10.3 6.1  13.6 5.7‡
0–1 year 10.7  11.2 6.5  13.1 4.2
EPMROM§
0–6 months 0.70  1.42 0.19  1.62 0.89¶
0–1 year 0.56  1.67 0.20  1.71 0.36
* QALYs quality-adjusted life years; SF-6D Short Form 6D; VAS visual analog scale; HAQHealth
Assessment Questionnaire; MACTAR  McMaster Toronto Arthritis Patient Preference Disability Ques-
tionnaire; EPMROM  Escola Paulista de Medicina Range of Motion scale.
† Mean  SD area under the curve during the study period.
‡ P  0.05 for differences between groups (Student’s t-test).
§ Mean  SD change scores from baseline to 6 or 12 months.
¶ P  0.01 for differences between groups (Student’s t-test).
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CI €235,000, €293,000). In 49% of the cases the interven-
tion was cost-saving. After 1 year of followup, the inter-
vention was cost-saving and IET was the dominant strat-
egy. The uncertainty around the ratio was estimated with
bootstrapping and is presented graphically by the cost-
utility plane (Figure 1). This plane shows in which quadrant
the population ratio can be expected. In Figure 1, 70% of
the bootstrapped ratios were situated in the lower-right quad-
rant (signifying lower costs and better quality of life) whereas
30% were situated in the upper-right quadrant (signifying a
gain in QALYs against higher costs). Because the SF-6D did
not show differences in QALYs between groups, the ICER
was not calculated based on this instrument.
Cost-effectiveness. The ICER was calculated based on
the MACTAR and EPMROM score over the first 6 months
because significant differences between groups in terms of
effectiveness were found with these instruments. The
ICER based on the MACTAR over the first 6 months was
€142 (€804/5.7) per score point (95% CI €2,328, €2,829):
in 38% of the cases the intervention was cost-saving. The
ICER based on the EPMROM over the first 6 months was
Table 3. Amount of medical and nonmedical resource use over the 0–6-month and 0–1-year study period comparing patients
in the intensive exercise therapy (IET) and usual care (UC) groups*
0–6 months 0–1 year
IET UC IET UC
General practitioner visits 2.5  2.7 3.7  4.8 4.9  4.2 7.6  8.9
Specialist visits 3.9  2.8 4.8  2.8 7.2  5.2 8.2  4.7
Physical therapist visits 14.5  15.4† 27.4  15.1 25.1  28.2† 41.5  25.6
Other paramedical professional visits 2.3  6.7 1.3  3.5 3.4  8.5 3.3  7.2
Hospitalization, no. of days‡ 15.7  13.9 21.3  19.7 17.2  14.1 27.9  34.0
No. of aids used 1.7  1.6 2.5  2.3 2.7  2.6 3.2  2.9
Professional domestic care, hours 46.1  58.0 44.1  74.4 79.7  105.1 72.5  122.1
Paid domestic help, hours 15.5  35.2 20  34.9 33.9  76.1 47.8  82.5
Informal care, hours 121  189.3 209  291.0 196.0  281.9 233.4  313.4
* Values are the mean  SD number per patient per period.
† P  0.01 for differences between groups (Mann-Whitney U test).
‡ Hospitalization includes hospital (academic or general), rehabilitation center, and nursing home.
Table 4. Mean total costs in euros per patient per year by cost category comparing patients in the intensive exercise therapy




(n  35) Difference 95% CI†
Medical costs
IET program‡ 2,991  256 NA 2,991
General practitioner 99  84 153  182 54
Specialist 426  372 489  354 63
Paramedical treatments 623  709 1,005  648 382
Alternative medicine 58  239 66  227 8
Hospitalization§ 9,363  7,389 12,444  9,927 3,081
Aids used 458  885 554  943 96
Medication 1,093  2,171 1,271  2,393 178
Total medical costs 15,111  8,462 15,983  11,327 872 6,210, 2,930
Direct nonmedical costs
Travel costs 133  327 133  191 0
Indirect nonmedical costs
Absenteeism 350  1,555 50  294 300
Domestic help 2,447  3,227 2,227  3,749 220
Formal care 252  565 322  570 70
Informal care 1,568  2,255 1,867  2,507 299
Total nonmedical costs 4,752  3,882 4,599  3,868 153 1,993, 1,620
Total costs 19,863  10,147 20,581  13,665 718 7,553, 3,660
Total costs (excluding IET program) 16,872  10,209 20,581  13,665 3,709 10,171, 1,120
* Values are the mean  SD costs per patient in 2003 euros. 95% CI  95% confidence interval; NA  not applicable.
† Double-sided bootstrapping.
‡ IET program  3 weeks of intensive exercise training in a dedicated convalescent hotel.
§ Hospitalization includes hospital (academic or general), rehabilitation center, and nursing home.
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€903 (€804/0.89) per score point (95% CI €16,741,
€5,621): in 32% of the cases IET was cost-saving.
DISCUSSION
This health-economic analysis demonstrates that after 1
year of followup, the IET program for patients with arthri-
tis immediately after hospital discharge is the dominant
strategy. It is associated with lower costs and better effec-
tiveness expressed as VAS personal health–based QALYs
gained compared with UC. After 6 months of followup,
IET is associated with slightly higher costs but a better
quality of life and improved gain in function compared
with UC.
The 2 QALY measures used in this study led to different
conclusions on the effectiveness of the intervention. This
can be explained by the fact that conceptual differences
exist in the measurement of utilities using the VAS and
SF-6D because they are based on different elicitation meth-
ods. The VAS general health is a direct measure of utility
representing the individual valuation of a single health
state on a rating scale, whereas the SF-6D is a preference-
based indirect utility measure in which the general public
is the source of values, representing a summary score of 6
health states (19). The VAS is preferable to the SF-6D as a
measure of patient-reported outcomes because the SF-6D
uses preferences from the general public. In health-eco-
nomic evaluation, however, the SF-6D is preferable as a
standardized measure of QALYs representing the societal
perspective. Both instruments have some disadvantages.
Rating scales such as the VAS have been found to be
subject to measurement bias (30) and should not be used
alone in a study (31). The SF-6D, however, might not be
sensitive to changes in the current study population. Ac-
cording to Stucki et al (32), the responsiveness of the SF-36
for patients undergoing total hip arthroplasty is rather
moderate, because many items from the physical ability
scale of the SF-36 reflect intermediate rather than extreme
levels of difficulty. This floor effect was also demonstrated
for the SF-6D: although the SF-6D has been shown to be a
responsive measure in diseases of mild to moderate sever-
ity, it struggles to distinguish between states of severe
health (33).
Although the MACTAR measures primary functional
ability, it combines information on functional limitations
with information on health-related quality of life. A key
advantage of using the MACTAR is the ability to detect the
impact of treatment on functional outcomes that are of
most importance to the patient. A limitation of this instru-
ment is that it is not widely used; little information on
other patients is available for comparison (34). Therefore,
the interpretation of the MACTAR results is rather diffi-
cult.
An improvement of 3 points on the MACTAR can be
interpreted to represent 1 less functional problem (7). In
the current study, patients in the IET group showed im-
proved functional ability as measured with the MACTAR.
The estimated score difference of 4.2 after 1 year in the
DAPPER study can be interpreted to indicate that patients
receiving IET had at least 1 less relevant individual activ-
ity problem after 1 year of followup, at €718 lower costs.
The DAPPER study demonstrates that IET reduces the
mean total health care costs of patients with arthritis from
a societal perspective in the first year after hospitalization.
The main difference was caused by the costs of hospital-
ization. However, no statistically significant difference be-
tween groups was found in amount expressed as total days
of hospitalization. Nevertheless, a trend showed that pa-
tients from the UC group stayed in the hospital longer
immediately after study start as well as during followup
because of (another) hospital admission. Essentially, high
hospitalization costs in the UC group in the first months
were caused by a small group of patients who were re-
ferred to a nursing home for a long period. During fol-
lowup, differences in costs between groups were mainly
caused by another small group of patients with extremely
long periods of hospitalization. In other words, it is note-
worthy that patients from the IET group did not need
nursing home care and were able to return home. More-
over, these patients needed less hospitalization in the year
of followup, which could be due to a higher level of
physical fitness. Because the UC group initially had more
patients with RA and less with OA compared with the IET
group, one should consider selection bias. However, this is
unlikely as all patients sent to a nursing home were diag-
nosed with OA.
Although not of great impact for the cost difference
between groups, a significant difference in favor of the IET
group was observed in the number of visits for physical
therapy. Obviously, the IET program included physical
therapy, which influenced the difference in the first 6
months of followup. Nevertheless, the number of visits to
the physical therapist continued to be lower in the IET
group during the entire year. A possible explanation might
be the instant favorable recovery.
This is the first study that addresses the difference in
total costs between usual care and an intensive convales-
cence treatment program in patients with arthritis who
were hospitalized because of a flare in disease activity or
for elective joint replacement. The results of the DAPPER
study are of great interest because the population is aging
and resources are limited. There are only a few studies on
Figure 1. Cost-utility plane: bootstrap replicates of costs per qual-
ity-adjusted life year (QALY) gained estimated using the visual
analog scale general health after 1 year of followup.
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cost-effectiveness of exercise in patients with arthritis (6–
10). However, except for the study by Mitchell et al (8),
patients scheduled for joint replacement surgery or pa-
tients with total knee or hip replacements were excluded
in these studies. Moreover, the definition of exercise dif-
fered greatly among the studies. Most authors concluded
that exercise therapy provided insufficient improvement
in health to justify the additional costs (6–8). Only Rich-
ardson et al (10) found that group-based exercise is likely
to be cost-effective compared with home-based exercise.
However, this 8-week, twice-weekly, group-based program
was only suitable for patients with knee OA.
This economic evaluation was conducted alongside a
randomized clinical trial. Therefore, all resource use and
health outcomes data were fully stochastic and were col-
lected prospectively over the 1-year study period. This is
an important strength of the current study because many
economic evaluations use modeling techniques that are
often based on indirect data and best guesses. Further-
more, the analysis was conducted from a societal perspec-
tive, which implies that all relevant costs (including the
indirect costs) were taken into account.
There are some limitations to the current study. First, as
described before, VAS personal health–based preferences
are not preferable as a standardized measure of QALYs for
use in societal-perspective economic evaluation; therefore,
caution should be taken with the interpretation of the
ICER. Furthermore, the number of patients lost to followup
was quite high: only 75% of the eligible patients could be
included in the analysis. Nevertheless, there were no sig-
nificant differences in baseline characteristics between the
evaluable and nonevaluable patients. Finally, when con-
sidering the human-capital method, there is a possibility
of overestimating the true societal costs. However, because
only 4 patients reported absenteeism from work, it proba-
bly had a limited effect on the results.
The results from this study demonstrate that IET therapy
is designated for all patients with arthritis (with the em-
phasis on those with polyarticular arthritic symptoms)
after hospital discharge. Implementation of IET therapy
should include the combination of intensive exercise and
group-based patient education in arthritis-dedicated facil-
ities in the presence of experienced care givers.
In conclusion, IET after hospitalization for patients with
arthritis due to a flare of disease activity or for elective
joint replacement results in better quality of life at lower
costs after 1 year compared with UC. This highlights the
need for implementation of IET after hospital discharge in
patients with arthritis.
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